results everyone you, of I our overview joining thoughts will second questions review for by us thanks today. quarter the answers. XXXX an of Starting operational conclude and turning second a and before of And performance, an Thank begin providing then Oasheim, the of rest call our financial with for by quarter. update, Mike. by with the CFO, Jared to today’s I’ll our followed our to review
seen States XX% to and expansion This an positive increase revenue of average impact Our of increase our by centers units to of execution existing expansion into campaigns. volume. increase we growth number our commercial of quarter an new revenue internationally. results total second record was million, in and business sold over a have an awareness was supported the centers, the by XXXX, of the $X.X in the Throughout in quarter from generated In Heart quarterly the strategy, continuing increase continued Failure growth United of second were the the over their XX% and implanting million, marketing implanting quarter. the due resulting approximately U.S., XXXX, of $X.X both driven XXXX. our These strategy,
see commercial second support quarter continued trends XXXX. adoption the to in you development we operational from during to encouraging the and the fourth use want I Europe give now on some quarter Additionally, an stemming of of Barostim. have update made greater to investments during
As a One, reminder, of the expansion and three, our are: expansion portfolio; Two, our commercial innovation continued focus the evidence. infrastructure; of areas clinical product of body the of
infrastructure, sales Let’s begin with commercial the direct organization. expansion continued specifically U.S. our of our
expect three Barostim add the The the about territories, new to we territories bringing three the expectations. and drive continues the organization XX, During exceed per to adoption of added of an quarter to average their sales of and our the XX quarter, new total finishing caliber ability territories. we to with year
our pilot education geographies, headway We select are direct-to-consumer is to branding making patient conducted positive support where with being our new in program campaign.
to to ways for expand program We optimize the will continue look we as further.
with device. our to aimed Barostim continued institutions patients patient select in about who education we Additionally, our are speaking already advance pilot physicians at
the program expanding to-date. made The the additional expanded our marketing and started with has direct-to-consumer to are gaining we we program program of progress first education pilot With successful, this and institutions. traction, been phase happy have both patient
rollout, these to support optimization the programs. expertise successful in in-house XXXX, continued continue of invest including of For will remainder to the of we the expansion, hiring the and growth
Barostim first of year, In related is product our of Our approval three on the half our received we platform. portfolio. of second to pre-market the innovation area focus supplements the clearance
under undergo Conditional MRI receive an allows Barostim for conditions. all who patients, Heart was MRI device Labeling, first which certain exam Barostim a have will received Failure to The or
our new average. programming generator, our XX% on longer factor And prior than was software. is size which simpler tablet and generation for was The second battery programmer, implantable for is a in even life which pulse with has new the form smaller an third
We in launching new the process platform. the of are now
occur is the in events, population first expected the with process, Heart clinical evidence. on BeAT-HF Fraction. more benefit and our track and the of we clinical with provide by final all of Our the expansion body time for mortality XXXX. third patient half un-blinding of collected review the believe to trial this focus the have necessary a which the continue morbidity events Reduced end to all detailed Failure remains designed of is accrue Barostim of year. line The of Once Ejection The to during demonstrate will will the BeAT-HF required we we
track In remain Guided our Implant Ultrasound BATwire, with on we addition, Toolkit.
half first we is second the quarter are performance for we what with it happy accomplish. XXXX, trial able the We continue some by XXXX validates chain fully inflation XXXX.Despite to in COVID, the of demand growing the in difficult immensely from in challenges end seen expect be Barostim. to were The approval of supply as to enrolled the and and expect FDA disruption encouraging
Looking commercial growth we ahead, plan financials. continued over XXXX. now Jared. the are the of on turn for to track to committed our and I’ll call to Jared remain balance our executing for review